Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnovAge HoldingINNV -2.03%66 10-Year RORE % is 0.00 as of Mar. 2026. GuruFocus rates INNV with a GF Score™ of 66/100 and a GF Value™ of $6.57 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 320 Healthcare Providers & Services companies, InnovAge Holding ranks worse than 312499.69% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
InnovAge Holding does not have enough data to calculate 10-Year RORE %.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
InnovAge Holding 10-Year RORE % Related Terms
InnovAge Holding 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for InnovAge Holding's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INNV vs HCSG, ARDT, AGL: 10-Year RORE % Comparison
For the Medical Care Facilities subindustry, InnovAge Holding's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnovAge Holding 10-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, InnovAge Holding's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where InnovAge Holding's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.
InnovAge Holding (INNV) has a 10-Year RORE % of 0.00 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on InnovAge Holding and its competitors. According to the industry distribution chart, InnovAge Holding ranks #999999 out of 320 companies in the Healthcare Providers & Services industry.
Is InnovAge Holding's 10-Year RORE % too high?
InnovAge Holding's current 10-Year RORE % is 0.00. Based on the distribution chart, InnovAge Holding ranks #999999 out of 320 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, InnovAge Holding has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InnovAge Holding's 10-Year RORE % compare to HCSG and ARDT?
According to the Healthcare Providers & Services industry distribution chart, InnovAge Holding ranks #999999 out of 320 companies for 10-Year RORE %. This places InnovAge Holding in the lower half of its industry. The industry median 10-Year RORE % is 7.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Healthcare Providers & Services company?
The median 10-Year RORE % among Healthcare Providers & Services companies is 7.12, based on 320 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on InnovAge Holding and its competitors. For the Healthcare Providers & Services industry, the median 10-Year RORE % is 7.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnovAge Holding's current 10-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnovAge Holding stock overvalued right now?
Based on GuruFocus' analysis, InnovAge Holding (INNV) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.57, compared to a current price of $11.34 — trading 72.6% above its estimated fair value. The current 10-Year RORE % is 0.00. InnovAge Holding's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For InnovAge Holding (INNV), the current 10-Year RORE % is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnovAge Holding (INNV) Overvalued in 2026?
Based on GuruFocus' analysis, InnovAge Holding stock appears to be overvalued.
The current stock price of $11.34 is trading 72.6% above its estimated GF Value™ of $6.57.
GuruFocus considers InnovAge Holding to be Significantly Overvalued.
Key valuation signals for INNV:
10-Year RORE %: 0.00
GF Value™: $6.57 vs. price of $11.34 (72.6% above fair value)
No single metric tells the full story. See the INNV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.
66GF Score
Get the complete analysis for INNV
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INNV has been successfully added to your 
